Wednesday, November 11, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleCrunchbase News

US Startup Funding Slows Sharply In March

View original at news.crunchbase.com
Crunchbase News - Funding Ma Title: US Startup Funding Slows Sharply In March Date: 2026-03-23 17:36 Source: https://news.crunchbase.com/business/us-startup-funding-slows-march-2026-data/ <p><span style="font-weight: 400;">After a rollicking start in </span><a href="https://news.crunchbase.com/ai/global-vc-investment-s…
Opening lines of the source · Crunchbase News · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • A $110 billion funding round will likely take years, not weeks or months, to be topped

    60% confidence
  • This month's funding deceleration is mostly a U.S. phenomenon

    60% confidence
  • The slowdown is almost entirely due to fewer giant AI megarounds closing this month

    60% confidence
  • American companies raised just around $13 billion in seed through growth-stage funding in March 2026 so far

    60% confidence
  • US startup funding slowed dramatically in March 2026 after strong January and February

    60% confidence
  • European startup funding hit its highest point of the year in March 2026

    60% confidence
  • February's U.S. funding tally will remain one for the record books

    60% confidence
  • Early- and seed-stage dealmaking in March is on track to come in close to the prior two months' levels

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com